Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity NewsBluebird Bio has agreed to sell itself to private equity firms Carlyle and SK Capital for $29 million to stabilize its gene therapy commercialization efforts.